Antibody · IL-17A

12개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved12 programs
AntibodyCurated CoreFDANovartisApproved

secukinumab (Cosentyx, AIN457)

Psoriasis, PsA, AS, nr-axSpA, HS · IL-17A

#IL-17A#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 229Status Approved
AntibodyCurated CoreFDAUCBApproved

bimekizumab (Bimzelx, UCB4940, bimekizumab-bkzx)

Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa · IL-17A / IL-17F

#IL-17AIL-17F#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 58Status Approved
AntibodyLimited DatastaleNovartisPhase 3

secukinumab (AIN457, AIN457 (secukinumab))

Asthma · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 148Status Active
AntibodyCurated CorestaleEli Lilly and CompanyApproved

Ixekizumab (Ixekizumab)

Psoriasis; Atopic Dermatitis · Psoriatic Arthritis

#PsoriaticArthritis#Antibody#Approved#BioJungboMoa-pick#Popular+5
Trials 53Status Recruiting
AntibodyLimited DatastaleNovartisPhase 3

Investigational Arm - secukinumab (Investigational Arm - secukinumab)

Plaque Psoriasis; Non-alcoholic Fatty Liver Disease · Plaque Psoriasis

#PlaquePsoriasis#Antibody#Phase3#monoclonal-antibody#Non-alcoholicFattyLiverDisease+1
Trials 5Status Discontinued
AntibodyLimited DatastaleNovartisPhase 3

Experimental: Secukinumab high dose (Experimental: Secukinumab high dose)

Chronic Severe Plaque-type Psoriasis · Chronic Severe Plaque-type Psoriasis

#ChronicSeverePlaque-typePsoriasi#Antibody#Phase3#monoclonal-antibody#Novartis
Trials 2Status Active
AntibodyLimited DatastaleNovartis PharmaceuticalsPreclinical

Secikinumab (Secikinumab)

Axial Spondylarthritis (axSpA); Secukinumab · Psoriasis

#Psoriasis#Antibody#Preclinical#monoclonal-antibody#AxialSpondylarthritisaxSpA+2
Trials 2Status Active
AntibodyLimited DatastaleNovartisPhase 1

Cosentyx（Secukinumab ） (Cosentyx（Secukinumab ）)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase1#monoclonal-antibody#Novartis
Trials 1Status Active
AntibodyLimited DatastaleSecond Affiliated Hospital, Sch…Approved

IL-17A/F mAb + NAFL (IL-17A/F mAb + NAFL)

Hidradenitis Suppurativa (HS) · Hidradenitis Suppurativa (HS)

#HidradenitisSuppurativaHS#Antibody#Approved#monoclonal-antibody#Second
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of secukinumab (Proactive TDM-based dosing of secukinumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#monoclonal-antibody#University
Trials 1Status Recruiting
AntibodyLimited DatastalePeking Union Medical CollegePreclinical

Surgery combined with secukinumab (Surgery combined with secukinumab)

Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa) · Hidradenitis Suppurativa (HS)

#HidradenitisSuppurativaHS#Antibody#Preclinical#monoclonal-antibody#HidradenitisSuppurativaAcneInver+1
Trials 1Status Recruiting